{"id":"NCT04295681","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders","officialTitle":"A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-12","primaryCompletion":"2023-02-07","completion":"2023-02-07","firstPosted":"2020-03-04","resultsPosted":"2024-10-28","lastUpdate":"2024-10-28"},"enrollment":246,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cognitive Disorders"],"interventions":[{"type":"DRUG","name":"MMH-MAP","otherNames":["Prospekta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MMH-MAP","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.","primaryOutcome":{"measure":"Average MoCA Score.","timeFrame":"On baseline and on 90th day of the treatment.","effectByArm":[{"arm":"MMH-MAP","deltaMin":20.7,"sd":3.5},{"arm":"Placebo","deltaMin":21.7,"sd":2.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":22,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":123},"commonTop":["Increased blood pressure","Asthenia","Headache","Bronchitis","Coronavirus infection COVID-19"]}}